Robert E. Landry - Nov 16, 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Nov 16, 2021
Transactions value $
-$941,470
Form type
4
Date filed
11/18/2021, 03:23 PM
Previous filing
Sep 1, 2021
Next filing
Dec 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $1.5M +3.75K +14.43% $399.66 29.7K Nov 16, 2021 Direct F1
transaction REGN Common Stock Tax liability -$2M -3.07K -10.32% $651.97 26.7K Nov 16, 2021 Direct F1
transaction REGN Common Stock Sale -$439K -681 -2.55% $645.08 26K Nov 17, 2021 Direct F1
holding REGN Common Stock 229 Nov 16, 2021 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -3.75K -15% $0.00 21.3K Nov 16, 2021 Common Stock 3.75K $399.66 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.